| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6495541 | CLOVIS ONCOLOGY INC | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
Nov, 2023
(a month from now) | |
| US8754072 | CLOVIS ONCOLOGY INC | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(7 years from now) | |
| US9045487 | CLOVIS ONCOLOGY INC | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7531530 | CLOVIS ONCOLOGY INC | Therapeutic compounds |
Jul, 2024
(9 months from now) | |
| US7351701 | CLOVIS ONCOLOGY INC | Therapeutic compounds |
Jul, 2024
(9 months from now) | |
| US8071579 | CLOVIS ONCOLOGY INC | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(3 years from now) | |
| US8143241 | CLOVIS ONCOLOGY INC | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(3 years from now) | |
| US9861638 | CLOVIS ONCOLOGY INC | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(7 years from now) | |
| US10278974 | CLOVIS ONCOLOGY INC | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(7 years from now) | |
| US8859562 | CLOVIS ONCOLOGY INC | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(7 years from now) | |
| US9987285 | CLOVIS ONCOLOGY INC | High dosage strength tablets of rucaparib |
Aug, 2035
(11 years from now) | |
| US10130636 | CLOVIS ONCOLOGY INC | High dosage strength tablets of rucaparib |
Aug, 2035
(11 years from now) | |
Rubraca is owned by Clovis Oncology Inc.
Rubraca contains Rucaparib Camsylate.
Rubraca has a total of 12 drug patents out of which 0 drug patents have expired.
Rubraca was authorised for market use on 19 December, 2016.
Rubraca is available in tablet;oral dosage forms.
Rubraca can be used as a method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; a method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation; a method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation, a method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; a method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation; a method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation, a method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation; a method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation, a method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation; a method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; a method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation.
The generics of Rubraca are possible to be released after 17 August, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 6, 2025 |
| New Indication (I) | May 15, 2023 |
Drugs and Companies using RUCAPARIB CAMSYLATE ingredient
Market Authorisation Date: 19 December, 2016
Treatment: A method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; A method for treating ovarian cancer by admin...
Dosage: TABLET;ORAL
RUBRACA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic